The blue-chip NSE Nifty 50 index gained 0.18% to 18,135.5, while the benchmark S&P BSE Sensex added 0.21% to 60,811.7
Indian shares rose on Monday, boosted by banking, auto, and pharmaceutical stocks, with sentiment aided by upbeat Asian markets following strong Chinese economic data.
The blue-chip NSE Nifty 50 index gained 0.18% to 18,135.5 and the benchmark S&P BSE Sensex added 0.21% to 60,811.7 by 0459 GMT.
The Nifty Pharma Index was up nearly 1.13%, led by Laurus Labs and Biocon Ltd that advanced 6.5% and 2.3% respectively.
Apollo Hospitals jumped 9% after the company’s net profit and revenue rose in the September quarter.
Top gainers on the indexes included government-run Oil and Natural Gas Corporation (ONGC), up as much as 4.91%, after reporting a near seven-fold jump in Q2 net profit.
Indian cosmetics-to-fashion platform FSN E-Commerce Ventures Ltd, which owns the Nykaa brand, dropped as much as 7.4% on Monday.
In its first earnings report following a blockbuster market debut last week, the Falguni Nayar-led Nykaa on Sunday reported a 96% slump in quarterly net profit, hurt by higher marketing and advertisement expenses.
Among market debutants, SoftBank-backed PolicyBazaar’s parent PB Fintech opened at a premium 17% to the IPO (Initial Public Offering) price. Refined wood pulp maker Sigachi Industries listed at a 250% premium over its IPO price of 163 rupees ($2.19).
The domestic market looks comfortable, with a lot of IPOs and an overall good quarterly performance by Indian companies, said Sumit Pokharna, VP Research at Kotak Securities.
He also said that the market was upbeat about the listing of new digital companies, and that the only concerns that remain are global factors such as inflation and a strengthening dollar.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.